Dashboard
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.53 times
- Poor long term growth as Net Sales has grown by an annual rate of 14.60% and Operating profit at 41.93% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.53 times
- The company has been able to generate a Return on Equity (avg) of 3.58% signifying low profitability per unit of shareholders funds
Low Debt Company with Strong Long Term Fundamental Strength
With a growth in Net Sales of 13.6%, the company declared Very Positive results in Sep 26
Stock is technically in a Mildly Bullish range
With ROCE of 9.8, it has a Very Expensive valuation with a 5.4 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
INR 16,908 Cr (Small Cap)
52.00
40
0.07%
0.24
8.89%
6.79
Total Returns (Price + Dividend) 
Latest dividend: 0.60309375 per share ex-dividend date: Sep-04-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Shilpa Medicare Ltd is Rated Hold by MarketsMOJO
Shilpa Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with the most recent insights into the company’s performance and outlook.
Read More
Shilpa Medicare Ltd Surges 7.22% to Day's High of Rs 1003 — Outperforms Sector by 7.42 Percentage Points
The Sensex inched up a modest 0.04% on 12 Nov 2026, while Shilpa Medicare Ltd surged 7.22% to touch an intraday high of Rs 1003, outperforming its Pharmaceuticals & Biotechnology sector by 7.42 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly steady market.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11-Nov-2026 | Source : BSEQ2FY27 Earnings Conference Call 05 November 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
05-Nov-2026 | Source : BSEAudio link of the Investor Conference call for the quarter ended 30 September 2026.
Update On Corporate Insolvency Resolution Process Of FTF Pharma Private Limited A Wholly Owned Subsidiary Of Shilpa Medicare Limited.
05-Nov-2026 | Source : BSEUpdate on Corporate Insolvency Resolution Process of FTF Pharma Private Limited a Wholly Owned Subsidiary of Shilpa Medicare Limited
Corporate Actions 
No Upcoming Board Meetings
Shilpa Medicare Ltd has declared 60% dividend, ex-date: 04 Sep 26
Shilpa Medicare Ltd has announced 1:2 stock split, ex-date: 06 Nov 15
Shilpa Medicare Ltd has announced 1:1 bonus issue, ex-date: 03 Oct 25
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
4.9047
Held by 13 Schemes (4.2%)
Held by 154 FIIs (12.11%)
Vishnukant Chaturbhuj Bhutada (6.51%)
Suraj Kumar Inani (4.01%)
27.73%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 13.60% vs 6.59% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -21.51% vs -6.41% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.66% vs 11.02% in Sep 2024
Growth in half year ended Sep 2025 is 184.22% vs 1,046.95% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 15.29% vs 11.13% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 112.50% vs 765.40% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 19.62% vs 11.71% in Mar 2025
YoY Growth in year ended Mar 2026 is 210.81% vs 145.65% in Mar 2025
